FATE THERAPEUTICS Business Summary

Fate Therapeutics Inc. (FATE) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic collaboration and license agreements, most notably with Ono Pharmaceutical. Its business model centers on the development of "off-the-shelf" cellular immunotherapies derived from its proprietary induced pluripotent stem cell (iPSC) product platform. The company operates through two primary therapeutic segments: immuno-oncology, focusing on natural killer (NK) and T-cell programs for solid tumors and hematologic malignancies, and immuno-regulation, targeting autoimmune disorders such as systemic lupus erythematosus (SLE) with its lead candidate FT819. Fate competes directly with other cell therapy innovators like Sana Biotechnology, Century Therapeutics, and Beam Therapeutics. Within this landscape, Fate distinguishes itself as a pioneer in the large-scale manufacture of clonal, multiplexed-engineered iPSC lines, positioning the firm as a leader in the transition from patient-specific CAR-T therapies to scalable, universal cell products. The company was founded in 2007 by a prestigious group of scientists, including Dr. Robert Langer of MIT, Dr. Rudolf Jaenisch of the Whitehead Institute, and Dr. Sheng Ding. The current leadership team is led by President and CEO Bahram (Bob) Valamehr, Ph.D., MBA, who assumed the role in January 2025 after nearly 15 years leading the company’s R&D efforts. He is supported by Chief Financial Officer Kamal Adawi, who joined in October 2025 with extensive experience in autoimmune-focused life science strategy, and Chief Legal Officer Cindy Tahl. The board is chaired by William Rastetter, Ph.D., a veteran biotech executive known for his leadership at Biogen Idec and Illumina. Fate is backed by prominent institutional investors and corporate partners, including Redmile Group LLC, BlackRock, and Johnson & Johnson, maintaining a well-capitalized balance sheet to support its registrational clinical trials through 2026.